Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of 173,303 exomes and genomes in the Pakistan Genome Resource.

Nature·2026
Same author

Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same author

Enhancing skin moisture and anti-aging by DL-α-tocopherol loading sodium alginate-based hydrogel microneedles.

Drug delivery and translational research·2026
Same author

Novel piperazine-triazole hybrids as PTP1B and alpha-amylase inhibitors: synthesis, biological evaluation and computational validation through network pharmacology, molecular docking, MD simulations, DFT and MMPBSA analysis.

RSC advances·2026
Same author

Coupled interfacial phenomena suppress propulsion in catalytic Janus colloids.

Physical review. E·2026
Same author

Clinical and Procedural Characteristics and In-Hospital Outcomes of Stent Thrombosis Following Primary Percutaneous Coronary Intervention (PCI).

Cureus·2026

Related Experiment Video

Updated: Jul 4, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Sinusitis: a possible link with adalimumab.

Muhammad Haroon1, Ursula Bond, Mark Phelan

  • 1Arthritis and Osteoporosis Centre, South Infirmary-Victoria University Hospital, Cork, Republic of Ireland. mharoon301@hotmail.com

Clinical Rheumatology
|June 27, 2008
PubMed
Summary
This summary is machine-generated.

This case series suggests adalimumab may increase the risk of chronic sinusitis in patients with inflammatory arthritis. Discontinuation of adalimumab resolved sinusitis, indicating a potential link between this TNF antagonist and recurrent sinus infections.

Related Experiment Videos

Last Updated: Jul 4, 2026

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification
10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Area of Science:

  • Rheumatology
  • Immunology
  • Otolaryngology

Background:

  • Anti-TNF agents are increasingly used for inflammatory arthritis.
  • Long-term adverse event data for TNF antagonists like adalimumab are still emerging.
  • Previous trials had limitations in sample size and duration for adverse event assessment.

Purpose of the Study:

  • To report a case series of patients developing sinusitis during adalimumab treatment.
  • To investigate the potential association between adalimumab and chronic sinusitis.
  • To highlight the clinical course and management of sinusitis in this context.

Main Methods:

  • Case series of four patients with refractory rheumatoid arthritis or psoriatic arthritis.
  • Treatment escalation to adalimumab (Humira).
  • Clinical assessment and diagnosis of sinusitis by otorhinolaryngologists.

Main Results:

  • Four patients developed newly diagnosed, recurring sinusitis within weeks of starting adalimumab.
  • Sinusitis was refractory to standard medical treatment.
  • Discontinuation of adalimumab led to the resolution of sinusitis in all patients.

Conclusions:

  • Adalimumab treatment may be associated with a higher incidence of chronic sinusitis than previously reported.
  • Physicians should be vigilant for sinusitis as a potential adverse event in patients on adalimumab.
  • Further research is warranted to confirm this association and elucidate the underlying mechanisms.